User menu

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Bibliographic reference Polman, Chris ; Kappos, Ludwig ; Freedman, Mark S ; Edan, Gilles ; Hartung, Hans-Peter ; et. al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.. In: Journal of neurology, Vol. 255, no.4, p. 480-7 (2008)
Permanent URL http://hdl.handle.net/2078.1/125005
  1. Barkhof F, Filippi M, Miller DH, et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (Pt 11):2059–2069
  2. Barkhof F, Rocca M, Francis G, et al. (2003) Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 53:718–724
  3. Beck RW, Chandler DL, Cole SR, et al. (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481–90
  4. Beck Roy W., Cleary Patricia A., Anderson Malcolm M., Keltner John L., Shults William T., Kaufman David I., Buckley Edward G., Corbett James J., Kupersmith Mark J., Miller Neil R., Savino Peter J., Guy John R., Trobe Jonathan D., McCrary John A., Smith Craig H., Chrousos Georgia A., Thompson H. Stanley, Katz Barrett J., Brodsky Michael C., Goodwin James A., Atwell Constance W., A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis, 10.1056/nejm199202273260901
  5. CHAMPS Study Group (2002) Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Mult Scler 8:405–409
  6. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782
  7. European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497
  8. Held U, Heigenhauser L, Shang C, Kappos L, Polman C (2005) Predictors of relapse rate in MS clinical trials. Neurology 65:1769–1773
  9. , Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, 10.1212/wnl.43.4.655
  10. Jacobs LD, Beck RW, Simon JH, et al. (2000) Intramuscular interferon beta- 1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904
  11. Kappos L, Polman CH, Freedman MS, et al. (2005) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249
  12. Korteweg T, Tintore M, Uitdehaag B, et al. (2006) MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 5:221–227
  13. Li DK, Held U, Petkau J, et al. (2006) MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66:1384–1389
  14. Miller DH, Molyneux PD, Barker GJ, et al. (1999) Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, doubleblind, placebo-controlled trial. Ann Neurol 46:850–859
  15. O'Connor P (2003) The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 25:2865–2874
  16. Paty D. W., Li D.K.B., , , Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, 10.1212/wnl.43.4.662
  17. Poser CM, Paty DW, Scheinberg L, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
  18. Soderstrom M., Ya-Ping J., Hillert J., Link H., Optic neuritis: Prognosis for multiple sclerosis from MRI, CSF, and HLA findings, 10.1212/wnl.50.3.708
  19. Tintoré M, Rovira A, Brieva L, Grivé E, Jardí R, Borrás C, Montalban X, Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS, 10.1177/135245850100700603
  20. Tintore M, Rovira A, Rio J, et al. (2005) Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 57:210–215
  21. Uitdehaag BM, Kappos L, Bauer L, et al. (2005) Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler 11:227–231